pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 18·1 min read
save

Moderna appoints Ester Banque as chief commercial officer and expands Stephen Hoge's responsibilities

Jun 18, 2026·read at Endpoints ↗Neutral

Moderna announced a leadership reshuffle as it readies for upcoming product launches.

The company named Ester Banque, who previously led U.S. operations at animal health firm Zoetis, as its new chief commercial officer.

President Stephen Hoge will take on additional duties, broadening his oversight of commercial activities.

Separately, the chief executive of Reunion Neuroscience has departed the company.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs”

read at Endpoints ↗
95 words · retrieved Jun 18
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Reunion Neuroscience Inc2
topics
HER2

related stories

  • May 7Angelini fortifies neurology portfolio with $4.1B buyout of CatalystEndpoints
  • May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive
  • May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive
  • May 6Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive